TELA Bio, Inc. (TELA)
| Market Cap | 183.47M |
| Revenue (ttm) | 26.76M |
| Net Income (ttm) | -32.45M |
| Shares Out | 14.50M |
| EPS (ttm) | -2.24 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,413 |
| Open | 12.45 |
| Previous Close | 12.49 |
| Day's Range | 11.91 - 12.69 |
| 52-Week Range | 11.03 - 18.00 |
| Beta | 1.66 |
| Analysts | Buy |
| Price Target | 19.00 (+50.2%) |
| Earnings Date | Nov 10, 2021 |
About TELA
TELA Bio, Inc., a medical technology company, focuses on the design, development, and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine...
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for TELA Bio stock is "Buy." The 12-month stock price forecast is 19.00, which is an increase of 50.20% from the latest price.
News
TELA Bio, Inc. (TELA) Reports Q3 Loss, Tops Revenue Estimates
TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of -9.62% and 4.85%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
TELA Bio Reports Strong Third Quarter 2021 Revenues Reflecting Continued Growth Driven by Increased Demand
MALVERN, Pa., Nov. 10, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue re...
TELA Bio Announces Publication of 12-Month Results from the BRAVO Study with Continued Positive Outcomes Through 24 m...
MALVERN, Pa., Nov. 09, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc . (NASDAQ: TELA), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcem...
TELA Bio to Participate in Three Upcoming Conferences
MALVERN, Pa., Nov. 08, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement mat...
Will TELA Bio, Inc. (TELA) Report Negative Q3 Earnings? What You Should Know
TELA Bio, Inc. (TELA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TELA Bio and Next Science Enter into Exclusive Distribution Agreement in the Plastic Reconstructive Market for Advanc...
Agreement includes exclusive right to sell and market Next Science's proprietary no rinse antimicrobial solution in the US and first right of negotiation for EU market upon CE Approval Agreement include...
TELA Bio to Announce Third Quarter 2021 Financial Results
MALVERN, Pa., Oct. 27, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement mat...
TELA Bio Appoints Roberto Cuca as Chief Operating Officer and Chief Financial Officer
MALVERN, Pa., Sept. 27, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement ma...
TELA Bio® Announces New Data on Use of OviTex in a Range of Hernia Repair Applications, Including Novel ReBAR (Reinfo...
Positive results presented at the 2021 Society of American Gastrointestinal and Endoscopic Surgeons Meeting show advancement in hernia repair options Positive results presented at the 2021 Society of Am...
TELA Bio's OviTex® Reinforced Tissue Matrix to be Featured in Three Presentations at SAGES 2021
Innovative medtech company celebrates upcoming poster presentations for its advanced hernia reinforcement material at industry-leading conference Innovative medtech company celebrates upcoming poster pr...
TELA Bio, Inc. (TELA) Reports Q2 Loss, Tops Revenue Estimates
TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of -16.33% and 18.09%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
TELA Bio: Q2 Earnings Insights
Shares of TELA Bio (NASDAQ:TELA) decreased 2.3% after the company reported Q2 results. Quarterly Results Earnings per share decreased 7.55% over the past year to ($0.57), which missed the estimate of ($...
TELA Bio Reports Record Second Quarter 2021 Revenues Driven by Increased Demand
MALVERN, Pa., Aug. 11, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue re...
TELA Bio, Inc. (TELA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
TELA Bio, Inc. (TELA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TELA Bio to Participate in Canaccord Genuity's 41st Annual Growth Conference
MALVERN, Pa., Aug. 03, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement mat...
NHS Surgeon First in Europe to Implant TELA Bio's OviTex® LPR Reinforced Tissue Matrix
Mr. Paul Wilson, Consultant General Surgeon, successfully completes complex hernia repair with minimally invasive approach Mr. Paul Wilson, Consultant General Surgeon, successfully completes complex her...
New Strong Sell Stocks for June 18th
OEG, EAF, RARE, EGRX, and TELA have been added to the Zacks Rank #5 (Strong Sell) List on June 18, 2021
TELA Bio to Participate in Upcoming JMP Securities Life Sciences Conference
MALVERN, Pa., June 14, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement mat...
TELA Bio to Participate in Upcoming Investor Conferences
MALVERN, Pa., May 21, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement mate...
TELA Bio Launches Post Market Study Of OviTex In Hernia Surgery
TELA Bio Inc (NASDAQ: TELA) has launched its second post-market study, BRAVO II, to evaluate the clinical performance of OviTex Reinforced Tissue Matrices in the robotic repair of ventral hernias. The s...
TELA Bio Initiates BRAVO II Study of OviTex® for the Robotic Repair of Ventral Hernias
MALVERN, Pa., May 19, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement mate...
TELA Bio, Inc. (TELA) Reports Q1 Loss, Tops Revenue Estimates
TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of -27.27% and 4.02%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
TELA Bio: Q1 Earnings Insights
Shares of TELA Bio (NASDAQ:TELA) rose in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 11.11% year over year to ($0.56), which missed the estim...
TELA Bio Announces First Quarter 2021 Financial Results
MALVERN, Pa., May 13, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing, and marketing innovative tissue rei...
TELA Bio to Announce First Quarter 2021 Financial Results
MALVERN, Pa., April 29, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement ma...